- Home
- APGE vs PRAX Comparison
APGE vs PRAX Comparison
Compare APGE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APGE | PRAX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | APGE | PRAX |
|---|---|---|
| Price | $77.22 | $275.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $100.00 | ★ $304.43 |
| AVG Volume (30 Days) | 818.6K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $26.20 | $26.70 |
| 52 Week High | $78.12 | $278.44 |
Technical Indicators
Market Signals| Indicator | APGE | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 72.86 |
| Support Level | $74.48 | $251.00 |
| Resistance Level | $76.87 | $278.44 |
| Average True Range (ATR) | 3.37 | 16.16 |
| MACD | -0.06 | 6.18 |
| Stochastic Oscillator | 91.13 | 93.19 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.